Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.
Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.
Details
News Market Reaction – ACON
The recorded move for ACON in the trading session of this news was +10.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com.
Event: Q3 Investor Summit
Date: August 20, 2024
Presentation Time: 4:00 PM ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51121
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.